FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol MADRIGAL PHARMACEUTICALS, INC.								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
MILLIGAN DAVID V					MADRIGAL PHARMACEO FICALS, INC.								X Directo	-	10% O	vner		
(Last) (First) (Middle)						[Mean]								(give title	Other (sbelow)	specify		
C/O MADRIGAL PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year)												
200 BARR HARBOR DRIVE, SUITE 400						06/27/2019												
		— 	If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable							
(Street)					and the control of the control								Line)					
WEST CONSHOHOCKEN PA 19428													X Form filed by One Reporting Person					
CONSHOROCKEN													Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 an		Securities Beneficially Owned Following		Ownership orm: Direct O) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) oi (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution curity or Exercise (Month/Day/Year) if any			Transaction Code (Instr				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$100.45	06/27/2019		A		10,000		(1)	0	6/27/2024	Common Stock	10,000	\$0.00	10,000	D			

Explanation of Responses:

1. The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

Remarks:

/s/ Brian Lynch, as attorney-infact for David V. Milligan 07/01/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.